Savara’s (SVRA) In-Line Rating Reiterated at Evercore ISI

Savara (NASDAQ:SVRA)‘s stock had its “in-line” rating reissued by analysts at Evercore ISI in a report issued on Wednesday,Benzinga reports. They presently have a $5.00 price target on the stock, down from their prior price target of $7.00. Evercore ISI’s price target would indicate a potential upside of 30.55% from the company’s previous close.

Several other equities research analysts have also recently commented on the company. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research report on Tuesday, October 1st. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Savara in a report on Tuesday, October 8th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.83.

Savara Stock Down 5.9 %

Shares of NASDAQ SVRA opened at $3.83 on Wednesday. Savara has a 12 month low of $3.28 and a 12 month high of $5.70. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $630.42 million, a price-to-earnings ratio of -9.12 and a beta of 1.02. The business has a 50-day moving average of $3.97 and a 200-day moving average of $4.22.

Savara (NASDAQ:SVRA) last announced its earnings results on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Sell-side analysts expect that Savara will post -0.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

A number of institutional investors have recently modified their holdings of the company. CANADA LIFE ASSURANCE Co acquired a new position in Savara during the 1st quarter worth $35,000. Choreo LLC acquired a new stake in shares of Savara in the 2nd quarter worth approximately $59,000. DRW Securities LLC purchased a new stake in Savara in the 2nd quarter valued at approximately $62,000. Principal Financial Group Inc. lifted its stake in Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after buying an additional 6,973 shares in the last quarter. Finally, Profund Advisors LLC purchased a new position in shares of Savara during the 2nd quarter worth $105,000. 87.93% of the stock is owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.